- Home
- TSHA vs PZZA Comparison
TSHA vs PZZA Comparison
Compare TSHA & PZZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSHA | PZZA |
|---|---|---|
| Founded | 2019 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | TSHA | PZZA |
|---|---|---|
| Price | $4.46 | $38.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $10.56 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.66% |
| EPS Growth | ★ 62.50 | N/A |
| EPS | N/A | ★ 0.90 |
| Revenue | $8,333,000.00 | ★ $2,068,421,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $36.07 |
| Revenue Growth | N/A | ★ 14.07 |
| 52 Week Low | $1.13 | $30.16 |
| 52 Week High | $6.02 | $55.74 |
Technical Indicators
Market Signals| Indicator | TSHA | PZZA |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 66.90 |
| Support Level | $4.41 | $35.50 |
| Resistance Level | $5.16 | $40.23 |
| Average True Range (ATR) | 0.20 | 1.98 |
| MACD | -0.00 | 0.65 |
| Stochastic Oscillator | 20.13 | 86.83 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.